Back to top
more

Quipt Home Medical (QIPT)

(Delayed Data from NSDQ)

$2.13 USD

2.13
244,549

-0.01 (-0.47%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $2.13 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Tops Q2 Earnings Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 366.67% and 4.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy Quipt (QIPT) Ahead of Earnings?

by Zacks Equity Research

Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.

Zacks Equity Research

Insulet (PODD) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy Quipt (QIPT) Ahead of Earnings?

by Zacks Equity Research

Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

QIPT vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

QIPT vs. BSX: Which Stock Is the Better Value Option?